Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Leukemia, Promyelocytic, Acute 27Leukemia, Myeloid, Acute 27Leukemia 16Myelodysplastic Syndromes 13Multiple Myeloma 9Neuroblastoma 5Melanoma 5Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myelomonocytic, Acute 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Hematologic Neoplasms 4Congenital Abnormalities 4Uterine Cervical Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Anemia, Refractory, with Excess of Blasts 3Thrombocytopenia 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Tretinoin × Clear all
NCT06358677 2026-02-13

FACE

University of Utah

Phase 2 Recruiting
25 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 1 Not yet recruiting
10 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03307148 2020-01-22

STAR_PAC

Barts & The London NHS Trust

Phase 1 Completed
29 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡